Gyre Therapeutics (GYRE) EBT (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of EBT data on file, last reported at -$9.2 million in Q1 2026.

• EBT for Q1 2026 came in at -$9.2 million, down 299.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.1 million (down 187.14% YoY), and the FY2025 annual result was -$5.2 million, down 530.07% from the prior year.
• EBT climbed to -$9.2 million in Q1 2026 per GYRE's latest filing, from -$19.7 million in the prior quarter.
• Over five years, EBT peaked at $51.6 million in Q2 2022 and troughed at -$100.3 million in Q4 2023.
• A 5-year average of -$4.8 million and a median of $3.9 million in 2024 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2023: EBT surged 359.42% in 2022, then tumbled 339.82% in 2023.
• A 5-year view of EBT shows it stood at -$22.8 million in 2022, then plunged by 339.82% to -$100.3 million in 2023, then jumped by 78.82% to -$21.2 million in 2024, then advanced by 7.28% to -$19.7 million in 2025, then surged by 53.1% to -$9.2 million in 2026.
• Business Quant data shows GYRE's EBT at -$9.2 million in Q1 2026, -$19.7 million in Q4 2025, and $7.6 million in Q3 2025.